Continuous Peripheral Nerve Block Catheters Market Report Scope and Overview:

The Continuous Peripheral Nerve Block Catheters Market was valued at USD 468.25 Million in 2025 and is projected to reach USD 796.81 Million by 2035, registering a CAGR of 5.46% from 2026 to 2035. The market continues expanding steadily.

The Continuous Peripheral Nerve Block Catheters Market is steadily reshaping postoperative pain management by moving surgical patients away from systemic opioids toward prolonged, site-specific regional analgesia delivered through indwelling perineural catheters. The market is characterized by rising adoption of enhanced recovery after surgery (ERAS) and opioid-sparing protocols, growing use of ultrasound guidance and AI-assisted anatomy recognition for accurate catheter placement, and expanding outpatient joint replacement that requires 48 to 72 hours of analgesia after same-day discharge. Significant growth is being witnessed in over-the-needle catheter designs and ambulatory surgical centre use, considering that hospitals, ASCs and pain clinics continue investing in regional techniques that shorten length of stay, reduce opioid consumption and improve rehabilitation.

A pilot feasibility study accepted for publication in Regional Anesthesia & Pain Medicine in September 2025 evaluated a percutaneous device that delivers both local anesthetic and electrical stimulation to peripheral nerves under a U.S. FDA investigational device exemption, reflecting the industry's broader shift toward multifunctional, longer-acting peripheral nerve analgesia.

Continuous Peripheral Nerve Block Catheters Market Trends

• Rising adoption of ERAS and opioid-sparing protocols continues embedding catheter-based analgesia in orthopedic care.

• Growing use of AI-assisted ultrasound guidance continues lowering the skill threshold for accurate catheter placement.

• Expanding outpatient joint replacement continues increasing demand for home-based continuous nerve block infusion.

• Increasing development of echogenic and antimicrobial catheter designs continues improving visibility and infection control.

• Rising dedicated reimbursement for non-opioid pain management continues supporting adoption in outpatient settings.

U.S. Continuous Peripheral Nerve Block Catheters Market Outlook

The U.S. Continuous Peripheral Nerve Block Catheters Market was valued at approximately USD 192.32 Million in 2025 and is projected to reach approximately USD 319.29 Million by 2035, registering a CAGR of approximately 5.2% from 2026 to 2035.

Demand across the United States continued to be shaped by the country's high volumes of total knee, hip and shoulder arthroplasty, national efforts to reduce postoperative opioid prescribing, and the rapid migration of joint replacement procedures from hospitals to ambulatory surgical centres. Rising use of ultrasound-guided continuous femoral, adductor canal, interscalene and popliteal sciatic blocks paired with elastomeric or electronic pumps continued reinforcing the country's position as the largest national market. Growing numbers of anesthesiology residency programmes requiring ultrasound proficiency added further layers of sustained domestic demand, with providers increasingly prioritizing catheter systems that support safe same-day discharge and remote patient follow-up.

CMS began providing separate Medicare payment in January 2025 under the NOPAIN Act for qualifying non-opioid pain management devices, including Avanos Medical's ON-Q elastomeric and ambIT electronic infusion pumps used with continuous nerve block catheters, removing a longstanding reimbursement barrier for American outpatient and ambulatory providers.

Continuous Peripheral Nerve Block Catheters Market Segment Analysis

• By Product Type, Non-Stimulating Catheter Systems segment dominated the Continuous Peripheral Nerve Block Catheters Market in 2025 with 55% share; Over-the-Needle Catheter Systems segment is the fastest growing segment with a CAGR of approximately 7.9%.

• By Insertion Technique, Ultrasound Guided segment dominated the Continuous Peripheral Nerve Block Catheters Market in 2025 with 51% share; Hybrid (Dual Guidance) segment is the fastest growing segment with a CAGR of approximately 8.2%.

• By Indication, Lower Extremity Surgeries segment dominated the Continuous Peripheral Nerve Block Catheters Market in 2025 with 38% share; Trauma Cases segment is the fastest growing segment with a CAGR of approximately 9.6%.

• By End User, Hospitals segment dominated the Continuous Peripheral Nerve Block Catheters Market in 2025 with 62% share; Ambulatory Surgical Centers segment is the fastest growing segment with a CAGR of approximately 8.9%.

By Product Type: Non-Stimulating Systems Lead, Over-the-Needle Systems Grow Fastest

The Non-Stimulating Catheter Systems segment dominated the Continuous Peripheral Nerve Block Catheters Market in 2025, driven by the widespread shift to ultrasound-guided placement, which removes the need for electrical stimulation to locate target nerves. Non-stimulating catheters are simpler to set up, faster to insert and less costly than stimulating equivalents, advantages that appeal to high-volume hospitals and cost-conscious ambulatory centres. Broad availability of non-stimulating kits from major regional anesthesia suppliers reinforced this segment's position as the largest contributor to total market revenue throughout the base year.

The Over-the-Needle Catheter Systems segment is the fastest growing in the Continuous Peripheral Nerve Block Catheters Market owing to their ability to seal the insertion site, reduce leakage of local anesthetic and resist dislodgement during patient mobilization. Over-the-needle designs allow single-operator placement and tighter catheter fit, supporting longer indwelling periods for ambulatory patients recovering at home. Rising adoption in outpatient shoulder and knee surgery is accelerating this segment's growth trajectory across ASCs and hospital outpatient departments worldwide. Growing use of echogenic markings further supports accurate placement under ultrasound.

By Insertion Technique: Ultrasound Guided Leads, Hybrid (Dual Guidance) Grows Fastest

The Ultrasound Guided segment dominated the Continuous Peripheral Nerve Block Catheters Market because real-time visualization of nerves, blood vessels and the spread of local anesthetic improves placement accuracy, lowers vascular puncture risk and shortens procedure time compared with landmark or stimulation-only techniques. Ultrasound guidance is now the standard of care in most academic and high-volume centres, and portable ultrasound units have become far more affordable for community hospitals. Widespread training of anesthesiologists in ultrasound-guided regional anesthesia reinforced this segment's dominant contribution to total market revenue throughout the base year.

The Hybrid (Dual Guidance) segment is the fastest growing as teaching hospitals and complex-case centres combine ultrasound imaging with nerve stimulation confirmation to maximize placement safety. Dual guidance is particularly valuable in patients with obesity, edema or distorted anatomy, where ultrasound images alone can be difficult to interpret. Rising emphasis on patient safety and resident training continues attracting investment in hybrid-compatible catheter systems. Growing availability of AI-assisted anatomy recognition tools further strengthens multi-modal verification approaches.

By Indication: Lower Extremity Surgeries Lead, Trauma Cases Grow Fastest

The Lower Extremity Surgeries segment dominated the Continuous Peripheral Nerve Block Catheters Market because total knee arthroplasty, hip fracture repair, foot and ankle surgery and amputations generate intense postoperative pain lasting several days. Continuous femoral, adductor canal, sciatic and popliteal catheters provide sustained analgesia that supports early mobilization and physical therapy. Growing volumes of knee and hip replacement among aging populations reinforced this segment's dominant contribution to total market revenue throughout the base year. Rising use of catheters in diabetic foot surgery and amputation further supported steady demand.

The Trauma Cases segment is the fastest growing due to rising numbers of road-traffic injuries, falls among older adults and hip fractures requiring prolonged pain control. Continuous nerve blocks started early after injury can reduce opioid use, lower delirium risk in elderly patients and support earlier surgery and rehabilitation. Expanding emergency department and trauma centre use of ultrasound-guided regional anesthesia continues attracting a broadening base of clinicians toward catheter techniques. Growing military and disaster medicine interest in field-deployable analgesia further widens this indication's addressable base.

By End User: Hospitals Dominate, Ambulatory Surgical Centers Grow Fastest

The Hospitals segment dominated the Continuous Peripheral Nerve Block Catheters Market because hospitals perform the largest share of major orthopedic, trauma and revision procedures and operate acute pain services that manage indwelling catheters. Inpatient teams can monitor catheter function, adjust infusion rates and manage complications around the clock. Continued hospital investment in regional anesthesia programmes and ERAS pathways reinforced this segment's dominant contribution to total market revenue throughout the base year. Growing hospital outpatient departments offering same-day joint replacement further supported demand.

The Ambulatory Surgical Centers segment is the fastest growing as same-day total joint replacement, shoulder arthroscopy and foot surgery shift to outpatient settings. Continuous catheters paired with portable infusion pumps allow patients to receive 48 to 72 hours of analgesia at home, making outpatient surgery safer and more comfortable. Expanding Medicare coverage for outpatient joint replacement and new non-opioid reimbursement continue attracting ASCs toward catheter-based regional anesthesia. Growing physician ownership of orthopedic ASCs continues accelerating adoption.

Regional Analysis

North America Continuous Peripheral Nerve Block Catheters Market Insights

North America dominated the Continuous Peripheral Nerve Block Catheters Market with the largest revenue share of approximately 46.2% in 2025. High orthopedic surgery volumes, strong regional anesthesia expertise, widespread ERAS adoption and national efforts to reduce opioid use continued reinforcing this dominant regional position. A large network of ambulatory surgical centres performing outpatient joint replacement created sustained demand for catheters that support home-based analgesia. Growing availability of dedicated reimbursement for non-opioid pain management devices further reinforced this region's leadership position.

The United States accounted for the substantial majority of regional revenue, anchored by more than one million knee replacements a year, rapid ASC growth and strong presence of leading catheter and infusion pump suppliers. Canada added further demand through provincial investment in ultrasound equipment and regional anesthesia training, and that combined strength kept the region the largest addressable market for CPNB catheter vendors through the forecast period. Continued expansion of outpatient orthopedic programmes reinforced sustained catheter demand.

Europe Continuous Peripheral Nerve Block Catheters Market Insights

Europe held a meaningful share of global revenue, supported by strong regional anesthesia traditions, high rates of hip and knee replacement and well-established ERAS programmes across the region's major economies. European anesthesiology societies continued promoting ultrasound-guided regional techniques through training and simulation programmes. Implementation of the EU Medical Device Regulation continued shaping product approval timelines and documentation requirements for catheter manufacturers. Growing day-case arthroplasty programmes further reinforced regional demand.

Germany continued to lead demand at roughly 25.40% of European revenue, supported by one of the world's highest rates of hip and knee replacement and a strong domestic base of regional anesthesia device makers such as B. Braun and PAJUNK. The UK, France and Italy contributed substantial additional demand through their national health services and growing day-surgery programmes, and continued European investment in opioid-sparing care should keep regional demand for CPNB catheters climbing through the forecast period. Additional demand from Spain, Switzerland and the Nordic countries reinforced broader regional market strength.

Asia Pacific Continuous Peripheral Nerve Block Catheters Market Insights

Asia Pacific is advancing at the fastest pace, growing at a CAGR of approximately 7.4% from 2026 to 2035. This growth is driven by rising orthopedic and trauma surgery volumes in China, India, Japan and Southeast Asia, expanding hospital infrastructure, growing availability of portable ultrasound and rising awareness of regional anesthesia benefits, with new surgical centres and trained anesthesiologists continuing to broaden the region's addressable base well beyond its traditional smaller footprint. Centralized procurement programmes are also improving access to lower-cost catheter kits.

China held a substantial share of regional revenue, supported by large surgical volumes, hospital expansion and volume-based procurement that lowers device prices. Japan and India contributed meaningful additional demand, with Japan's aging population and high hip fracture burden and India's expanding private hospital chains standardizing ultrasound-guided protocols both reinforcing the region's position as the fastest-growing market tracked in this report. Australia, South Korea and Southeast Asian countries contributed smaller but steadily growing regional demand throughout the period.

MEA and Latin America Continuous Peripheral Nerve Block Catheters Market Insights

The Middle East and Africa and Latin America both showed steady growth, driven by expanding surgical capacity, rising orthopedic and trauma case volumes and growing investment in anesthesia services across both areas. As these markets continue building regional anesthesia expertise, continuous nerve block catheters offer an effective way to reduce opioid dependence and shorten hospital stays. Growing private hospital investment and medical tourism across both regions further reinforced device adoption.

Saudi Arabia led Middle East and Africa demand, supported by health sector transformation and anesthesia capacity investment under Vision 2030. The UAE and South Africa contributed further demand through private hospital networks and growing focus on opioid stewardship. In Latin America, Brazil accounted for the largest share of regional revenue, with its large public hospital system and growing orthopedic surgery volumes continuing to anchor regional demand for CPNB catheters. Mexico and Argentina contributed additional demand through expanding private surgical services.

Market Dynamics

Growth Drivers: Rising Orthopedic Surgery Volumes and Opioid-Sparing Care Protocols

The industry is driven by rising global volumes of knee, hip and shoulder replacement, a growing hip fracture burden among aging populations, and strong clinical and policy momentum behind opioid-sparing multimodal analgesia. As hospitals and surgeons continue adopting ERAS pathways that recommend continuous peripheral nerve blocks for major limb surgery, demand for catheter kits, securement devices and infusion systems continues rising across hospitals and ambulatory centres worldwide. Growing evidence that catheters shorten length of stay and improve rehabilitation further reinforces this sustained industry-wide demand driver.

Rising technical capability of regional anesthesia tools continues reinforcing this driver, as higher-resolution portable ultrasound, AI-based nerve identification software, echogenic catheters and over-the-needle designs make placement faster and more reliable. Growing integration with elastomeric and electronic infusion pumps and remote patient follow-up continues supporting safe home-based analgesia, and that combination of clinical value and workflow efficiency keeps demand rising at a steady, sustained pace. Expanding training and simulation programmes are further widening the addressable user base.

Restraints: Catheter Complications and Limited Regional Anesthesia Expertise

Risks of catheter dislodgement, leakage, infection and local anesthetic toxicity continue posing a restraint on faster market-wide expansion, particularly for longer infusions and home-based use. Catheter placement takes more time than single-injection blocks and requires follow-up resources that smaller centres may lack. The growing availability of long-acting local anesthetic formulations for single-shot blocks also offers an alternative for some procedures.

A shortage of anesthesiologists trained in advanced ultrasound-guided regional techniques continues posing a further restraint, particularly in tier-2 hospitals and developing regions. Device and procedure costs, together with limited reimbursement in many countries, keep some facilities reliant on opioid-based analgesia. Stricter regulatory evidence requirements continue prolonging launch timelines for new catheter designs in several regions.

Opportunities: AI-Guided Placement and Home-Based Ambulatory Analgesia

Rising investment in AI-assisted ultrasound guidance, smart catheters with sensors and connected infusion pumps represents a significant opportunity, as providers seek to make regional anesthesia easier to learn and safer to extend into the home. Vendors positioned early in integrated catheter, pump, software and training ecosystems stand to capture meaningful share as continuous nerve blocks become a standard part of outpatient surgery. Expanding non-opioid reimbursement programmes continue widening this addressable opportunity.

Closing regional anesthesia gaps across emerging markets offers a second substantial opportunity, as rising surgical volumes, hospital construction and anesthesiology training continue creating fresh demand for catheter-based analgesia. Vendors with cost-effective catheter kits and strong clinical education support stand to capture meaningful share as developing economies expand surgical capacity. Continued growth of private hospital networks across India, China, the Middle East and Latin America is further accelerating local technology adoption.

Recent Developments:

• July 2026: Avanos Medical, Inc., maker of the ON-Q and ambIT pain management systems used with continuous nerve block catheters, received all required regulatory approvals for its pending acquisition by affiliates of American Industrial Partners under a merger agreement signed in April 2026.

• July 2026: Zimmer Biomet completed its acquisition of the iovera cryoanalgesia system from Pacira BioSciences, adding a drug-free, nerve-targeted pain management device to its orthopedic portfolio.

• August 2025: SmartAlpha received U.S. FDA 510(k) clearance for Nerveblox, an AI software solution that identifies anatomical structures in real time across 12 ultrasound-guided nerve block procedures.

• July 2025: Bioventus Inc. received U.S. FDA 510(k) clearances for TalisMann and StimTrial, two next-generation peripheral nerve stimulation products for chronic pain management.

• January 2025: Pacira BioSciences received U.S. FDA clearance for a new iovera Smart Tip designed to access the medial branch nerves for managing chronic low back pain.

• January 2025: B. Braun Medical introduced the Clik-FIX Epidural/Peripheral Nerve Block Catheter Securement Device, expanding its catheter-stabilization portfolio for regional anesthesia.

Continuous Peripheral Nerve Block Catheters Market key players are:

• B. Braun SE

• Teleflex Incorporated

• Avanos Medical, Inc.

• PAJUNK GmbH Medizintechnologie

• Vygon SAS

• ICU Medical, Inc.

• Becton, Dickinson and Company (BD)

• Epimed International, Inc.

• Solo-Dex, Inc.

• Ace Medical Co., Ltd.

• Henan Tuoren Medical Device Co., Ltd.

• Ambu A/S

• Summit Medical Products, Inc.

• Advin Health Care

• Owens & Minor, Inc.

• Scilex Holding Company

• Pacira BioSciences, Inc.

• SPR Therapeutics, Inc.

• Bioventus Inc.

Continuous Peripheral Nerve Block Catheters Market: